Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
Overview
BiomX Inc (symbol: PHGE) is a clinical-stage microbiome company that employs cutting-edge synthetic and computational biology to develop both natural and engineered phage therapies. Using proprietary platforms and deep scientific expertise, BiomX customizes phage compositions to target and eradicate pathogenic bacteria linked to chronic conditions such as inflammatory bowel disease, colorectal cancer, primary sclerosing cholangitis, and pulmonary infections in cystic fibrosis patients. Key industry keywords such as 'phage therapy', 'drug discovery', and 'synthetic biology' underscore its approach to addressing unmet needs in chronic disease management.
Scientific and Technological Foundation
At the heart of BiomX’s innovation is its rigorous process of discovering and validating specific bacterial targets. The company utilizes a proprietary platform, often referred to as BOLT (BacteriOphage Lead to Treatment), to design customized phage cocktails. These therapies are developed through a blend of natural selection and precise engineering, ensuring that each therapeutic formulation is optimized to neutralize harmful bacterial strains. BiomX leverages state-of-the-art research conducted by leading scientists from institutions such as the Weizmann Institute of Science and the Massachusetts Institute of Technology, underscoring its commitment to scientific excellence.
Business Model and Market Position
BiomX’s operational strategy revolves around its robust pipeline of phage-based treatments that have been designed to address conditions with significant clinical unmet needs. The company generates value by advancing clinical-stage candidates through rigorous clinical trials and methodological research, positioning itself as a notable innovator in the specialized segment of microbiome drug discovery. Its approach centers on leveraging both natural phage therapies and engineered formulations, which are validated through robust preclinical and early clinical studies. This dual approach not only diversifies its product candidates but also ensures flexibility in targeting diverse bacterial infections.
Clinical Programs and Therapeutic Pipeline
BiomX is actively engaged in multiple clinical programs that demonstrate its commitment to transforming treatment paradigms in infectious diseases. Notably, the company has developed a fixed multi-phage cocktail intended for chronic pulmonary infections caused by Pseudomonas aeruginosa, one of the key pathogens in cystic fibrosis-related morbidity. In addition, its personalized phage treatment candidate is tailored to address infections such as diabetic foot osteomyelitis caused by Staphylococcus aureus. Each of these programs represents a significant effort to bridge the gap between innovative science and practical therapeutic applications.
Research, Development, and Expertise
BiomX’s research and development efforts are deeply rooted in academic and clinical collaborations. Drawing on the expertise of renowned professors and clinical researchers, the company’s development pipeline is informed by the latest discoveries in microbiome science and phage biology. This collaboration enables BiomX to stay at the forefront of phage therapeutic research, ensuring that its drug candidates are backed by robust scientific data and peer-reviewed findings. The integration of computational biology has further streamlined the process of identifying optimal phage-bacteria interactions and allowed for precision in treatment customization.
Competitive Landscape and Differentiation
The competitive landscape in microbiome and phage therapy is rapidly evolving, yet BiomX differentiates itself through its comprehensive platform and its dual approach of natural and engineered solutions. Unlike more generalized antibiotic treatments, BiomX’s therapies are specifically designed to target pathogenic bacteria while maintaining the integrity of beneficial microbiota. This targeted treatment modality, supported by strong clinical validation and collaborations with top-tier research institutions, positions BiomX as a company with a focused and innovative market approach.
Long-Term Value and Investor Considerations
For investors and stakeholders seeking to understand the company’s role in addressing chronic infectious diseases, BiomX offers a transparent view into a business model that prioritizes scientific validity and technological prowess. Its phased clinical programs provide clarity on how each candidate is developed and validated, while its strategic partnerships and experienced team enhance its credibility in the field. The company’s focus on a niche market, combined with its pioneering research in phage therapies, makes it a subject of interest for those evaluating innovative biotech ventures from an unbiased, research-driven perspective.
Conclusion
BiomX Inc is a compelling example of modern drug discovery where precision medicine meets advanced microbiome science. With its rigorous approach to targeting harmful bacteria in chronic diseases through customized phage therapies, the company has established a strong foundation of expertise, trust, and technological innovation. The comprehensive research, clinical collaborations, and structured pipeline make BiomX a notable name in the biotechnology and microbiome space, with an ongoing commitment to expanding the boundaries of conventional treatment paradigms.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on phage therapies, has disclosed that its independent registered public accounting firm included a going concern qualification in their audit opinion for the fiscal year ended December 31, 2024. This disclosure, which was previously included in the Company's annual report on Form 10-K filed on March 25, 2025, is being announced separately to comply with NYSE American Company Guide Sections 401(h) and 610(b). The company emphasizes that this announcement does not represent any changes or amendments to their 2024 audited financial statements or annual report.
BiomX (NYSE: PHGE) announced positive topline results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). The trial demonstrated that BX211 was safe and well-tolerated, producing statistically significant improvements in multiple areas:
- Sustained reduction in ulcer size (PAR) with p=0.046 at week 12
- Significant improvements in ulcer depth at week 13 (p=0.048)
- Reduced expansion of ulcer area (p=0.017)
The study involved 41 patients randomized at a 2:1 ratio, with 26 receiving BX211 and 15 receiving placebo. Treatment showed separation from placebo starting at week 7, with a difference greater than 40% by week 10. The company is now planning for a Phase 2/3 trial, pending FDA feedback.
BiomX (NYSE: PHGE) announced its Q4 and full year 2024 financial results, highlighting key developments in its phage therapy programs. The company secured $12 million in financing in February 2025 to support its Phase 2b study of BX004. Key financial metrics include:
- Cash balance of $18.0 million as of December 31, 2024
- R&D expenses increased to $24.7 million in 2024
- Net loss decreased to $17.7 million in 2024
- Operating cash burn of $37 million in 2024
Clinical Updates:
- BX211 Phase 2 topline results for diabetic foot osteomyelitis expected by end of March 2025
- BX004 Phase 2b topline results for cystic fibrosis anticipated in Q1 2026
- Received $36.8 million in non-dilutive funding from DHA for BX211 trial
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has announced it will release its fourth quarter and full year 2024 financial results on March 25, 2025.
The financial results will be accessible through a press release in the Investors section of BiomX's website. The company plans to host a conference call and audio webcast at a later date, which will coincide with the announcement of initial topline results from its Phase 2 trial investigating treatments for subjects with diabetic foot osteomyelitis.
BiomX Inc. (NYSE American: PHGE) has secured $12 million in financing through a series of offerings, including a registered direct offering and concurrent private placement. The funding will support the advancement of their BX004 program through Phase 2b study in cystic fibrosis patients, with topline results expected in Q1 2026.
The offerings were led by Deerfield Management Company with significant participation from the Cystic Fibrosis Foundation and Nantahala Capital. The financing includes the purchase of 3,633,514 shares of common stock at $0.9306 per share, along with warrants for additional shares. The company will also analyze real-world evidence exploring the relationship between P. aeruginosa reduction and clinical outcomes in CF patients.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.
BiomX announced Q3 2024 financial results and clinical program updates. Patient enrollment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is complete, with topline results expected in Q1 2025. The BX004 Phase 2b study in Cystic Fibrosis faced manufacturing delays, now resolved, with results expected in H1 2026. Cash balance was $24.7M as of September 30, 2024. R&D expenses increased to $7.3M from $5.6M year-over-year. The company reported net income of $9.6M compared to a net loss of $7.9M in Q3 2023, mainly due to changes in warrant fair value. Cash runway extends into Q4 2025.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing phage therapies targeting specific pathogenic bacteria, has announced a mandatory separation of its units (PHGE.U). Each unit consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American.
Key points:
- Unit holders will receive the underlying shares of Common Stock and Warrants
- The separation is automatic, requiring no action from unit holders
- Warrants will expire on October 28, 2024
- Each warrant allows purchase of one-half share at $115 per share
- Post-separation, Common Stock will trade under the symbol PHGE
BiomX Inc. (NYSE American: PHGE) will present updated data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference in Boston. The findings will be showcased in a poster session on September 27, 2024, and discussed in a workshop on September 28, 2024.
Key results include:
- Greater reduction in P. aeruginosa colony-forming units in subjects receiving BX004-A compared to placebo
- 14% of BX004-A recipients had negative P. aeruginosa sputum culture at treatment end, versus 0% for placebo
- Improved lung function (FEV1) in a subgroup of BX004-A recipients (+5.66%) compared to placebo (-3.23%)
The study's six-month follow-up has been completed for all subjects.
FAQ
What is the current stock price of Biomx (PHGE)?
What is the market cap of Biomx (PHGE)?
What is the core focus of BiomX Inc?
How does BiomX develop its phage therapies?
Which chronic conditions are targeted by BiomX’s therapies?
What distinguishes BiomX's approach from traditional therapies?
What role does scientific collaboration play at BiomX?
How is BiomX positioned within the competitive landscape?
What technology platforms does BiomX utilize?
Is BiomX involved in clinical trials?
